Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
August 02, 2021 16:05 ET
|
Recro Pharma, Inc.
EXTON, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Appoints Erica Raether as Vice President of People, Culture and ESG
July 20, 2021 07:00 ET
|
Recro Pharma, Inc.
EXTON, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Enters Development and Manufacturing Agreement With New Client
July 13, 2021 07:00 ET
|
Recro Pharma, Inc.
GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
Recro Reports Inducement Grants for New Staff
July 07, 2021 07:00 ET
|
Recro Pharma, Inc.
EXTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Appoints Laura L. Parks, Ph.D. to Board of Directors
June 16, 2021 07:00 ET
|
Recro Pharma, Inc.
EXTON, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Expands Capabilities for Growing Clinical Trial Services (CTS) Offerings
June 02, 2021 07:00 ET
|
Recro Pharma, Inc.
GAINESVILLE, Ga., June 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
Recro Enters Development Agreement With Astex Pharmaceuticals
May 18, 2021 07:00 ET
|
Recro Pharma, Inc.
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 14, 2021 09:15 ET
|
Recro Pharma, Inc.
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $34.5 Million EXTON, Pa., May 14, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and...
Recro Announces Pricing of $30.0 Million Public Offering of Common Stock
May 12, 2021 08:30 ET
|
Recro Pharma, Inc.
EXTON, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Announces Proposed Public Offering of Common Stock
May 11, 2021 16:30 ET
|
Recro Pharma, Inc.
EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...